FY2024 Earnings Estimate for Dynavax Technologies Co. (NASDAQ:DVAX) Issued By William Blair – MarketBeat

Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:

Dynavax Technologies Co. (NASDAQ:DVAX – Get Rating) – Research analysts at William Blair decreased their FY2024 earnings per share (EPS) estimates for Dynavax Technologies in a report issued on Tuesday, June 7th. William Blair analyst M. Phipps now forecasts that the biopharmaceutical company will post earnings of ($0.71) per share for the year, down from their prior estimate of ($0.01). William Blair also issued estimates for Dynavax Technologies’ FY2025 earnings at ($0.33) EPS. Dynavax Technologies (NASDAQ:DVAX – Get Rating) last released its earnings results on Thursday, May 5th. The biopharmaceutical company reported $0.22 EPS for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.02). The firm had revenue of $113.99 million during the quarter, compared to analysts’ expectations of $117.76 million. Dynavax Technologies had a net margin of 23.12% and a return on equity of 87.36%. During the same quarter in the previous year, the business earned $0.01 EPS.
A number of other research firms have also recently commented on DVAX. TheStreet upgraded Dynavax Technologies from a “d+” rating to a “c” rating in a research note on Wednesday, March 30th. StockNews.com cut Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Thursday, May 12th. Finally, Zacks Investment Research cut Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, March 1st. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, Dynavax Technologies has an average rating of “Hold” and an average target price of $21.00.
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!

When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
DVAX opened at $12.02 on Friday. The stock has a market cap of $1.52 billion, a PE ratio of 21.85 and a beta of 1.41. The company has a quick ratio of 1.85, a current ratio of 2.02 and a debt-to-equity ratio of 0.77. The business has a 50 day moving average of $10.40 and a 200-day moving average of $12.07. Dynavax Technologies has a 52 week low of $7.26 and a 52 week high of $21.39.
In other news, insider Justin Burgess sold 6,000 shares of the business’s stock in a transaction on Tuesday, May 17th. The stock was sold at an average price of $10.00, for a total value of $60,000.00. Following the completion of the transaction, the insider now owns 3,854 shares in the company, valued at $38,540. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 9.31% of the stock is currently owned by insiders.
Hedge funds have recently bought and sold shares of the company. Marshall Wace LLP bought a new stake in shares of Dynavax Technologies in the third quarter worth $98,295,000. State Street Corp grew its holdings in shares of Dynavax Technologies by 36.1% in the first quarter. State Street Corp now owns 8,498,732 shares of the biopharmaceutical company’s stock worth $92,126,000 after acquiring an additional 2,253,376 shares during the period. Edmond DE Rothschild Holding S.A. grew its holdings in shares of Dynavax Technologies by 430.0% in the first quarter. Edmond DE Rothschild Holding S.A. now owns 2,445,000 shares of the biopharmaceutical company’s stock worth $26,504,000 after acquiring an additional 1,983,700 shares during the period. Two Sigma Advisers LP grew its holdings in shares of Dynavax Technologies by 298.7% in the third quarter. Two Sigma Advisers LP now owns 2,034,188 shares of the biopharmaceutical company’s stock worth $39,077,000 after acquiring an additional 1,524,000 shares during the period. Finally, Millennium Management LLC grew its holdings in shares of Dynavax Technologies by 394.0% in the fourth quarter. Millennium Management LLC now owns 1,770,509 shares of the biopharmaceutical company’s stock worth $24,911,000 after acquiring an additional 1,412,111 shares during the period. Hedge funds and other institutional investors own 76.80% of the company’s stock.
Dynavax Technologies Company Profile (Get Rating)
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
Featured Articles

Earnings History and Estimates for Dynavax Technologies (NASDAQ:DVAX)
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Dynavax Technologies, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Dynavax Technologies wasn’t on the list.
While Dynavax Technologies currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The 5 Stocks Here

Complete the form below to receive the latest headlines and analysts’ recommendations for your stocks with our free daily email newsletter:
Kate chats with financial advisor and asset manager Marc Scudillo, who discusses some psychological aspects of investing in the current market, as well as the benefits of specific asset classes and investing styles.
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.
Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.
Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.
As Featured By:
MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.
Twitter Facebook StockTwits Financial Juice YouTube

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.

source

Related Articles